bortezomib,lenalidomide,dexamethasone,daratumumab
janssen,takeda
4-year efs 70.9% vs 50.5% favoring d-rvd
final analysis of griffin study by #mmsm #ims2022 
Washington U. School of Medicine.
Assoc Director Hem/Onc Fellowship.
Myeloma, Amyloidosis, Leukemia, Lymphoma & BMT physician and researcher.
Tweets are my own.